CDK4 and triple-negative breast carcinoma: Inhibition of CDK4/6 and CDK2 function using biochemical inhibitors suppresses the growth of triple negative breast cancer cells with low PPM1A, suggesting PPM1A as a biomarker to predict sensitivity to CDK inhibitors for more effective treatment of triple negative breast cancer.